Substituted indoline derivatives as dengue viral replication inhibitors
The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
1. A compound selected from the group consisting of:
and stereoisomeric forms, pharmaceutically acceptable salts, solvates or polymorphs thereof.
2. A pharmaceutical composition comprising the compound of claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.
3. The compound as claimed in claim 1 wherein the compound is
or a pharmaceutically acceptable salt, solvate or polymorph thereof.
4. A pharmaceutical composition comprising a compound of claim 3 together with one or more pharmaceutically acceptable excipients, diluents or carriers.
5. A compound of claim 1 having the formula 4:
or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof.
6. A compound or a stereoisomer, a pharmaceutically acceptable salt, solvate, or polymorph thereof according to claim 1 , wherein said compound is in a crystalline form.
7. A compound or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof according to claim 1 , wherein said compound is in an amorphous form.
8. A compound or a stereoisomer, a pharmaceutically acceptable salt, solvate, or polymorph thereof according to claim 1 , wherein said compound is in an un-solvated form.